Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1070806 plus standard of care for prevention of delayed graft function after renal transplantation
2015-002812-33Phase 2Terminated
- Sponsor
- GSK
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aletekitug in delayed graft function (DGF), sponsored by GSK. Primary endpoint: Proportion of subjects requiring dialysis during the first 7 days post transplant. Started Dec 2015; status: terminated.
02
Drugs
aletekitug
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on 2015-002812-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002812-33.